Insight journal, Insight journal - Company

Biocon: The first Indian biotech company to achieve many milestones

Posted on 12 May 2014

Tags: , ,

Biocon is an emerging biopharmaceutical enterprise that focuses on reducing the therapy costs associated with chronic diseases such as diabetes, cancer and autoimmune diseases.

Today Biocon is India’s largest biotech company employing over 7,000 professionals, developing and manufacturing small molecules, biosimilars, branded formulations, novel molecules and research services. Biocon is the developer behind INSUGEN, the world’s first pichia-based recombinant human insulin.

Biocon was established on Nov 29th 1978 as a joint venture between Irish Biocon Biochemicals and Indian entrepreneur Kiran Mazumdar- Shaw. From that day forth Biocon became the first Indian company to achieve many milestones; in 1979 it was the first Indian company to manufacture and export enzymes to USA and Europe and in 1989 it became the first Indian company to receive US funding for proprietary innovations after it officially split from Biocon Biochemicals that were bought by Unilever. In 2000 India’s first CRO was set up by them, Clinigene.

Partnerships, rather than acquiring

As with any other company Biocon could not achieve what it has today without the help of others companies that have offered the use of their products and services. Biocon has signed many partnerships throughout its history with companies including Bristol-Myers Squibb, Mylan Laboratories, Pfizer and GE capital. Many of the deals have been manufacturing and supply deals.

Since 2009, Biocon has signed over 15 partnering, collaborative R&D and licensing deals. It is notable though that Biocon hasn’t participated in many M&A’s.  The main M&A deal that Biocon was part of was the acquisition for Biocon Biopharmaceuticals Private Limited (BBPL) in 2010 from CIMAB SA who owned a 49% equity stake. 

Figure 1: Biocon partnering deals 2009-2014

Figure 1: Biocon partnering deals 2009-2014

Figure 1: Biocon partnering deals 2009-2014

In January of this year Biocon signed a key licensing deal with Advaxis to co-develop and commercialize ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)- associated cervical cancer in women for India and key emerging markets. Within the agreement Advaxis will manufacture and supply ADXS- HPV to Biocon and provide the commercialization rights for India.

Partnering outreach

Biocon is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Other events with Biocon’s presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with Biocon in person visit Current Partnering’s Event calendar.     

Contacting Biocon for partnering

Biocon can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:   

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events.   

Direct contact: there are several sources of direct contact with Biocon’s business development team

-        Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-        Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Biocon’s website has details for contacting Biocon.

-        LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.

Many of Biocon business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Biocon Linkedin Page.  

Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on Biocon website for potential partnering opportunities and general contact names.   

Raveena Bhambra    


Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Biocon 2009-2014

Biocon partnering at Current Agreements

View all partnering deals for Biocon:  2014 | 2013 | 2012 | 2011 | 2010 | 2009 

Full details on each deal can be found at Current Agreements (subscription required)

Or purchase report: Partnering Agreements with Biocon 2009-2014


Summary profile data for Biocon

Partnering activity for Biocon

M&A activity for Biocon


Available reports from Current Partnering

Report: Partnering Agreements with Biocon 2009-2014

Report: Partnering Deals and Alliances with Big Biotech


Available resources for deal coverage for Biocon

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Biocon company profile, recent partnering, M&A and financing news and articles



Report: Finding Biopharma Licensing and Collaboration Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply